Yuanyuan Meng1, Zhihui Xu1, Fangfang Wu1, Wenming Chen1, Shuangshuang Xie1, Jun Liu2, Xuefeng Huang1, Ying Zhou3. 1. Center for Reproductive Medicine, First Affiliated Hospital of Wenzhou Medical University, Wenzhou, People's Republic of China. 2. Stem Cells and Reprogramming Group, Biological Engineering Laboratories, Monash University, Clayton, Victoria, Australia. 3. Center for Reproductive Medicine, First Affiliated Hospital of Wenzhou Medical University, Wenzhou, People's Republic of China; Department of Histology and Embryology, Wenzhou Medical University, Wenzhou, People's Republic of China. Electronic address: zy-yin@163.com.
Abstract
OBJECTIVE: To investigate the antiapoptosis effect of sphingosine-1-phosphate (S1P) on human fetal ovarian tissue treated by cyclophosphamide (CTX). DESIGN: Experimental animal study. SETTING: University center for reproductive medicine and IVF unit. ANIMAL(S): Female immunodeficient BALB/c nude mice, 6 to 8 weeks old. INTERVENTION(S): Human fetal ovarian tissue slowly cryopreserved then subcutaneously transplanted in immunodeficient mice. MAIN OUTCOME MEASURE(S): Follicle survival assessed qualitatively and quantitatively using H&E staining, and cellular apoptosis of the ovarian grafts evaluated using transmission electron microscopy and DNA nick end labeling in situ (TUNEL assay). RESULT(S): The alkylating agent CTX caused a substantial follicle loss and apoptotic DNA fragmentation in the ovarian grafts in a period of 2 weeks of transplantation. The S1P treatment significantly prevented follicular apoptosis and maintained primordial follicle population in the grafts. CONCLUSION(S): This study shows for the first time that S1P protects primordial follicles in human ovarian grafts from a chemotherapy drug treatment via suppressing follicle apoptosis.
OBJECTIVE: To investigate the antiapoptosis effect of sphingosine-1-phosphate (S1P) on human fetal ovarian tissue treated by cyclophosphamide (CTX). DESIGN: Experimental animal study. SETTING: University center for reproductive medicine and IVF unit. ANIMAL(S): Female immunodeficient BALB/c nude mice, 6 to 8 weeks old. INTERVENTION(S): Human fetal ovarian tissue slowly cryopreserved then subcutaneously transplanted in immunodeficientmice. MAIN OUTCOME MEASURE(S): Follicle survival assessed qualitatively and quantitatively using H&E staining, and cellular apoptosis of the ovarian grafts evaluated using transmission electron microscopy and DNA nick end labeling in situ (TUNEL assay). RESULT(S): The alkylating agent CTX caused a substantial follicle loss and apoptotic DNA fragmentation in the ovarian grafts in a period of 2 weeks of transplantation. The S1P treatment significantly prevented follicular apoptosis and maintained primordial follicle population in the grafts. CONCLUSION(S): This study shows for the first time that S1P protects primordial follicles in human ovarian grafts from a chemotherapy drug treatment via suppressing follicle apoptosis.
Authors: Farners Amargant; Sharrón L Manuel; Megan J Larmore; Brian W Johnson; Maralee Lawson; Michele T Pritchard; Mary B Zelinski; Francesca E Duncan Journal: Biol Reprod Date: 2021-05-07 Impact factor: 4.285
Authors: N Spears; F Lopes; A Stefansdottir; V Rossi; M De Felici; R A Anderson; F G Klinger Journal: Hum Reprod Update Date: 2019-11-05 Impact factor: 15.610